CLDI logo

Calidi Biotherapeutics (CLDI)

Profile

Full Name

Calidi Biotherapeutics, Inc.

Ticker Symbol

CLDI

Country

United States

IPO

November 1, 2021

Indexes

Not included

Employees

41

Key Details

Price

$0.44(+7.84%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$2.97(+82.86% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Jun 27, 24 Ladenburg Thalmann
Buy
May 15, 24 Baird
Outperform
Mar 21, 24 HC Wainwright & Co.
Buy
Mar 21, 24 Baird
Outperform
Nov 22, 23 HC Wainwright & Co.
Buy
Oct 9, 23 Baird
Outperform

Institutional Ownership

  • What is the ticker symbol for Calidi Biotherapeutics?
  • Does Calidi Biotherapeutics pay dividends?
  • What sector is Calidi Biotherapeutics in?
  • What industry is Calidi Biotherapeutics in?
  • What country is Calidi Biotherapeutics based in?
  • When did Calidi Biotherapeutics go public?
  • Is Calidi Biotherapeutics in the S&P 500?
  • Is Calidi Biotherapeutics in the NASDAQ 100?
  • Is Calidi Biotherapeutics in the Dow Jones?
  • When was Calidi Biotherapeutics's last earnings report?
  • When does Calidi Biotherapeutics report earnings?
  • Should I buy Calidi Biotherapeutics stock now?

What is the ticker symbol for Calidi Biotherapeutics?

The ticker symbol for Calidi Biotherapeutics is NYSE American:CLDI

Does Calidi Biotherapeutics pay dividends?

No, Calidi Biotherapeutics does not pay dividends

What sector is Calidi Biotherapeutics in?

Calidi Biotherapeutics is in the Healthcare sector

What industry is Calidi Biotherapeutics in?

Calidi Biotherapeutics is in the Biotechnology industry

What country is Calidi Biotherapeutics based in?

Calidi Biotherapeutics is headquartered in United States

When did Calidi Biotherapeutics go public?

Calidi Biotherapeutics's initial public offering (IPO) was on November 1, 2021

Is Calidi Biotherapeutics in the S&P 500?

No, Calidi Biotherapeutics is not included in the S&P 500 index

Is Calidi Biotherapeutics in the NASDAQ 100?

No, Calidi Biotherapeutics is not included in the NASDAQ 100 index

Is Calidi Biotherapeutics in the Dow Jones?

No, Calidi Biotherapeutics is not included in the Dow Jones index

When was Calidi Biotherapeutics's last earnings report?

Calidi Biotherapeutics's most recent earnings report was on Mar 31, 2025

When does Calidi Biotherapeutics report earnings?

The next expected earnings date for Calidi Biotherapeutics is May 14, 2025

Should I buy Calidi Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page